Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Reduction of Inflammatory Status on Glucose Metabolism in Overweight Men

This study has been completed.
Sponsor:
Information provided by:
TNO
ClinicalTrials.gov Identifier:
NCT00221052
First received: September 13, 2005
Last updated: October 10, 2006
Last verified: October 2006

September 13, 2005
October 10, 2006
June 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00221052 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Effect of Reduction of Inflammatory Status on Glucose Metabolism in Overweight Men
Relation Between Reduction of the Inflammatory Status and Glucose Metabolism in Healthy Overweight Men

Overweight increases the risk to develop chronic diseases including type-2 diabetes and cardiovascular disease. The low-grade inflammatory status often seen in overweight subjects is thought to play an important role in disease development.

The purpose of this study is to determine the role of inflammation on glucose metabolism and insulin resistance. In this study the effect of the anti-inflammatory treatment diclofenac on markers of inflammation and on parameters of glucose metabolism will be studied.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
  • Overweight
  • Obesity
  • Inflammation
Drug: Diclofenac
Not Provided
van Erk MJ, Wopereis S, Rubingh C, van Vliet T, Verheij E, Cnubben NH, Pedersen TL, Newman JW, Smilde AK, van der Greef J, Hendriks HF, van Ommen B. Insight in modulation of inflammation in response to diclofenac intervention: a human intervention study. BMC Med Genomics. 2010 Feb 23;3:5. doi: 10.1186/1755-8794-3-5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
July 2005
Not Provided

Inclusion Criteria:

  • Body Mass Index (BMI): 25.1 – 32.0 kg/m2
  • Normal Dutch eating habits

Exclusion Criteria:

  • diabetes, cardiovascular disease or hypertension
  • Not suitable to receive diclofenac treatment
  • Smoking
  • Extreme physical activity (more than 6 hours/week)
  • Reported slimming or medically prescribed diet
Male
18 Years to 60 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT00221052
TNO-P6374
Not Provided
Not Provided
TNO
Not Provided
Principal Investigator: Trinette van Vliet, PhD TNO Quality of Life, Location Zeist
TNO
October 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP